The fusion of antigen-primed B-cells with transformed myeloma cells results in immortalized hybridomas that secrete antibodies (see Chapter 4). The subsequent cloning of the hybridomas gives rise to cell lines that secrete monoclonal antibodies (MAbs) of a single specificity (1). This technology has had a tremendous impact on research and medicine, with MAbs being used to identify and characterize the biological significance of myriads of molecules. The outcome has been the development of diagnostic tests and therapies for the detection and management of disease (2). The amount and purity of a MAb required for any given purpose can vary greatly. Here, we
From: Methods in Molecular Biology, vol. 295: Immunochemical Protocols, Third Edition. Edited by: R. Burns © Humana Press Inc., Totowa, NJ
describe the procedures involved in the maintenance and management of hybridomas and suggest techniques for maximizing yields.
Was this article helpful?